BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE and FOETAL EXPOSURE DURING PREGNANCY

Overview

FOETAL EXPOSURE DURING PREGNANCY is the #13 most commonly reported adverse reaction for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, manufactured by INDIVIOR INC.. There are 1,044 FDA adverse event reports linking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE to FOETAL EXPOSURE DURING PREGNANCY. This represents approximately 1.8% of all 59,605 adverse event reports for this drug.

Patients taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE who experience foetal exposure during pregnancy should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

FOETAL EXPOSURE DURING PREGNANCY is a less commonly reported adverse event for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.

Other Side Effects of BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE

In addition to foetal exposure during pregnancy, the following adverse reactions have been reported for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE:

• DRUG DEPENDENCE — 4,275 reports
• DRUG WITHDRAWAL SYNDROME — 3,327 reports
• PAIN — 2,543 reports
• OFF LABEL USE — 2,061 reports
• OVERDOSE — 1,850 reports
• NAUSEA — 1,627 reports
• EMOTIONAL DISTRESS — 1,472 reports
• ANXIETY — 1,348 reports
• VOMITING — 1,336 reports
• HEADACHE — 1,109 reports

Other Drugs Associated with FOETAL EXPOSURE DURING PREGNANCY

The following drugs have also been linked to foetal exposure during pregnancy in FDA adverse event reports:

Does BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE cause FOETAL EXPOSURE DURING PREGNANCY?

FOETAL EXPOSURE DURING PREGNANCY has been reported as an adverse event in 1,044 FDA reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is FOETAL EXPOSURE DURING PREGNANCY with BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE?

FOETAL EXPOSURE DURING PREGNANCY accounts for approximately 1.8% of all adverse event reports for BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, making it a notable side effect.

What should I do if I experience FOETAL EXPOSURE DURING PREGNANCY while taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE?

If you experience foetal exposure during pregnancy while taking BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages